Monitoring for Norepinephrine Infusion Side Effects
Monitor closely for extravasation and tissue ischemia at the infusion site (checking every 2 hours), hypertension (blood pressure every 2-5 minutes initially), bradycardia, and cardiac arrhythmias, as these represent the most clinically significant adverse effects of norepinephrine therapy. 1
Critical Cardiovascular Monitoring
Blood Pressure Surveillance
- Record blood pressure every 2 minutes from initiation until target MAP is achieved 1
- Once stable, continue monitoring every 5 minutes during ongoing infusion 1
- Watch for dangerously high blood pressure (>220 mmHg systolic) which can occur with overdosage 1
- Headache may signal hypertensive crisis from excessive dosing 1
Cardiac Rhythm Complications
- Bradycardia occurs as a reflex response to increased blood pressure and is common 2, 1
- Monitor for arrhythmias, particularly when combined with certain anesthetics (cyclopropane, halothane) or in patients with hypoxia/hypercarbia 1
- Stress cardiomyopathy is a recognized complication 1
- Risk increases significantly with concurrent MAOI or tricyclic antidepressant use 1
Infusion Site Monitoring (Critical for Peripheral Administration)
Extravasation Prevention
- Inspect infusion site every 2 hours for swelling, blanching, or paleness 3, 4
- Never leave patient unattended during infusion 1
- Extravasation occurs in approximately 2.3-3% of peripheral administrations but rarely causes severe injury with proper monitoring 3, 5
Site-Specific Risks
- Prefer large veins (antecubital preferred; femoral acceptable) 1
- Avoid leg veins in elderly patients or those with occlusive vascular disease (atherosclerosis, diabetes, Buerger's disease) due to higher gangrene risk 1
- Blanching along the vein may indicate vasa vasorum constriction even without obvious extravasation—consider changing site 1
- Tissue necrosis can occur from potent vasoconstriction if extravasation is undetected 1
Organ Perfusion Complications
Renal and Peripheral Ischemia
- Monitor for decreased renal perfusion and subsequent kidney dysfunction, particularly with prolonged high-dose infusion 1
- Watch for signs of peripheral ischemia (pallor, coolness, pain in extremities) 1
- Gangrene of extremities has been reported, though rare 1
- Risk of lactic acidosis from tissue hypoxia with severe vasoconstriction 1
Volume Depletion
- Plasma volume depletion can occur with prolonged administration 1
- This may cause rebound hypotension when norepinephrine is discontinued 1
- Ensure adequate fluid resuscitation concurrent with vasopressor therapy 6
High-Risk Patient Populations
Hypersensitive individuals (particularly hyperthyroid patients) may develop severe hypertension with violent headache, photophobia, retrosternal pain, intense sweating, and vomiting even at conventional doses 1
Common Pitfalls to Avoid
- Do not use catheter tie-in technique—obstruction around tubing increases local drug concentration 1
- Avoid proximal catheter placement when using peripheral access—associated with more adverse events 3
- Do not administer with halogenated anesthetics without extreme caution due to arrhythmia risk 1
- Never use as monotherapy without adequate volume resuscitation—this increases risk of severe vasoconstriction and organ ischemia 1
The FDA labeling emphasizes that constant vigilance is essential, as the potency of norepinephrine and variable patient responses create potential for serious complications 1. However, recent evidence demonstrates that with proper protocols including frequent site inspection and early intervention for extravasation, peripheral administration can be safe, with no cases of severe tissue injury requiring surgical intervention in large prospective studies 3, 5.